• BioXcel Therapeutics to Participate in Two Upcoming Healthcare Investor Conferences

    Source: Nasdaq GlobeNewswire / 04 May 2021 06:00:00   America/Chicago

    NEW HAVEN, Conn., May 04, 2021 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (“BioXcel” or the “Company”) (Nasdaq: BTAI), a clinical-stage biopharmaceutical company utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology, today announced that Dr. Vimal Mehta, Founder and Chief Executive Officer of BioXcel, will participate in two upcoming virtual healthcare investor conferences.

    Presentation Details:

    Event: BofA Securities 2021 Virtual Health Care Conference

    Format: Fireside Chat

    Date: Tuesday, May 11, 2021

    Time: 8:45 AM ET


    Event: UBS Global Healthcare Virtual Conference

    Format: Corporate Presentation

    Date: Tuesday, May 25, 2021

    Time: 2:00 PM ET

    Live webcasts from the BofA and UBS presentations and accompanying presentation materials will be accessible through the Investors section of the Company's website at www.bioxceltherapeutics.com. Following the conferences, the webcasts will be archived on the BioXcel Therapeutics, Inc. website for at least 30 days.

    BioXcel Therapeutics, Inc.

    BioXcel Therapeutics, Inc. is a clinical-stage biopharmaceutical company utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology. BioXcel's drug re-innovation approach leverages existing approved drugs and/or clinically validated product candidates together with big data and proprietary machine learning algorithms to identify new therapeutic indices. BioXcel's two most advanced clinical development programs are BXCL501, an investigational, proprietary, orally dissolving thin film formulation of dexmedetomidine for the treatment of agitation and opioid withdrawal symptoms, and BXCL701, an investigational, orally administered, systemic innate immunity activator in development for the treatment of aggressive forms of prostate cancer and advanced solid tumors that are refractory or treatment naïve to checkpoint inhibitors. For more information, please visit www.bioxceltherapeutics.com.

    BioXcel Therapeutics, Inc.

    www.bioxceltherapeutics.com


    Investor Relations:

    Mary Coleman

    BioXcel Therapeutics, VP of Investment Relations

    MColeman@bioxceltherapeutics.com 

    1.475.238.6837


    John Graziano

    Solebury Trout

    jgraziano@soleburytrout.com 

    1.646.378.2942 


    Media:

    Julia Deutsch

    Solebury Trout

    jdeutsch@soleburytrout.com 

    1.646.378.2967


    Primary Logo

Share on,